Company intelligence / Profile preview

Sibylla Biotech

Ownership: Private
Development stage: Preclinical

Overview

Sibylla Biotech is developing small molecule degraders with a novel mechanism of action that interferes with protein folding. Their lead asset is a Cyclin D1 degrader proceeding towards the clinic.

Therapeutic areas: OncologyNeurology
Modalities: Small molecules (Folding Interfering Degraders - FIDs)
Industry: Biotech

Partnerships

Takeda Pharmaceutical (exploratory discovery partnership in CNS space)Ono Pharmaceutical (strategic discovery and development deal in CNS space)MD Anderson (collaboration on small-molecule protein degraders)

Beyond the preview

Go deeper on Sibylla Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sibylla Biotech.

Explore the full profile